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ABSTRACT: Introduction: Static- and moving 2-point discrimination
(S2PD, M2PD), 10-g monoﬁlaments- and tuning fork are validated
outcome measures of clinical manifestations of diabetes-related
neuropathy. No modern statistical techniques have been used to
investigate how well these instruments combine to measure sensory
loss.Methods: To grade sensory loss at the feet, we ﬁtted paramet-
ric forms of Item Response Theory models to the data of these
instruments.Results: The ﬁt statistics indicate that the loss of sensa-
tion is gradable, with readily available instruments. S2PD and
M2PD are lost ﬁrst, followed by vibration sense, the 10-g monoﬁla-
ment and the ability to feel a cold stimulus. Conclusions: This test
battery appears to provide sound measurement properties in a
group of diabetic patients with diverse amounts of sensory loss. This
approach may be used in clinical practice to grade sensory loss reli-
ably and quickly, with instruments that are easy to use.
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Sensory loss due to diabetic sensorimotor poly-
neuropathy (DSP) can be assessed using noninvasive
and readily available screening instruments such as a
tuning fork, static- and moving 2-point discrimina-
tion (S2PD and M2PD) and monoﬁlaments.1–7
Each instrument tests different somatosensory func-
tions that are progressively lost during diabetes, in the
context of DSP.8–11 S2PD, for example, tests the slowly
adapting type I afferent Aß large-ﬁber system in the
skin, with the Merkel cell-neurite complex as peripheral
receptors. M2PD tests both the quickly adapting type I
afferent Aß ﬁber system, with Meissner corpuscles as
mechanoreceptors, as well as the quickly adapting type
II afferent Aß ﬁber system, with Pacinian corpuscles as
somatosensory receptors. The latter system is also tested
when performing vibratory testing.12,13 Static 1-point dis-
crimination (S1PD, e.g., monoﬁlaments) tests the slowly
adapting type I Aß system, with the Merkel cell-neurite
complex as mechanoreceptors. To establish the exact
temporal sequence in which these sensory functions are
lost, thereby grading the degree of sensory loss, mea-
surement properties of each instrument need to be clar-
iﬁed in relation to each other.
To investigate how well instruments combine to
measure sensory loss, we applied parametric forms of
item response theory (IRT) to the tests used in the
Rotterdam Diabetic Foot (RDF) study. IRT is a set of
mathematical models (e.g., the Rasch model) that
describe the relationship between an individual’s
“ability” or “trait” and how they respond to test
items.14–16 In short, IRT assumes that patients with a
higher ability (less ill) should have a greater chance
of obtaining a nonaberrant score on an item. Thus,
the probability of a response to an item depends on
the differences between the ability of the person and
the difﬁculty of the item. With this information, rela-
tive patient disability can be rank ordered on an indi-
vidual level by measuring patient ability (in this study
foot sensation) and comparing this to the ability of
each individual test item to differentiate between dis-
ability levels. Moreover, parametric IRT models can
be used to explore individual ability range, identify ﬁt-
ting and misﬁtting items to the models and investigate
differential item functioning (DIF) between sub-
groups of patients, which is indicative of item bias.
The purpose of this study was to evaluate the psy-
chometric properties of the 39-item Rotterdam Dia-
betic Foot Study Test Battery (RDF-39), to explore
how test instruments and test locations on the foot
compare, to create an outcome measure of foot sen-
sation on a continuous scale and investigate in which
areas of the trait (i.e., foot sensation) test informa-
tion is rich or scarce.
MATERIALS AND METHODS
Study Design and Subjects. Between January 2014 and
June 2015, a total of 416 subjects with type 1 and type 2 diabe-
tes were assessed prospective for the sensory status of their feet
Additional supporting information may be found in the online version of
this article.
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at the outpatient Diabetes Clinic of the Franciscus Gasthuis,
Rotterdam, the Netherlands as part of the RDF-study to inves-
tigate the deterioration of sensation in their feet over time.
Baseline RDF-data are used for this cross-sectional analysis.
Inclusion criteria were: patients diagnosed with diabetes melli-
tus (treated by oral blood glucose lowering drugs and/or insu-
lin), age over 18 years, speaking Dutch or English, and no
signiﬁcant cognitive impairment. Exclusion criteria were:
active radicular syndrome and neurological disease interfering
with sensation of the feet, as assessed in the interview and
screening questionnaire. Demographic data were obtained
from the patient ﬁle. All subjects provided written informed
consent. The institutional review board and the Medical Ethi-
cal Committee of Erasmus MC Medical University Center, Rot-
terdam, the Netherlands approved the study (MEC-2009-148).
Measurement Instrument. To test the different somato-
sensory functions at multiple sites of the feet, a battery of tests
was used. The RDF-39 includes both instruments and test sites
to measure overall foot sensation and consists of 39 individual
items that measure the unidimensional construct of foot sen-
sation.17 This scoring system contains dichotomized items on
static- and moving 2-point discrimination (S2PD and M2PD),
static 1-point discrimination (S1PD), vibration sense, cold
stimulus tests, Romberg’s test, experienced numbness, prior
diabetic foot ulcer and prior amputation. S2PD and M2PD
were tested with a Disk-Criminator™ (US Neurologicals, LCC,
Poulsbo, WA), with the threshold set at 8 mm (abnormal: > 8
mm), based on previously published normative values.4 S1PD
was tested with a 10 g Semmes-Weinstein monoﬁlament
(Baseline® Tactile™, Minneapolis, MN), based on current
international standards of medical care in diabetes.2,3 S2PD,
M2PD, and S1PD test sites were chosen in concordance with
the nerve territories of the foot: I, plantar hallux (medial plan-
tar nerve [tibial nerve]); II, medial heel (calcaneal nerve [tib-
ial nerve]); III, ﬁrst dorsal web (deep peroneal nerve); IV,
lateral foot (sural nerve) and V, plantar ﬁfth toe (lateral
planter nerve [tibial nerve]), see Supplementary Figure SA,
which is available online. M2PD was not tested at the ﬁfth toe
due to its small surface area.
Vibration sense was tested with a Rydel-Seiffer tuning fork
(Martin, Tuttlingen, Germany) at the medial malleolus and
dorsal interphalangeal joint of the hallux and compared with
normative threshold data.6 Cold sensation was tested by apply-
ing a cold piece of metal to the arch of the foot. Information
on numbness was derived from the Michigan Neuropathy
Screening Instrument (MNSI), which was administered before
the physical examination. Information on prior ulceration
and/or amputation, as indicators of severe sensory loss, was
derived from the patient interview. Sensory test items con-
sisted of both a sensory test and test location (e.g., S1PD at
the lateral foot [S1PD IV], S2PD at the plantar ﬁfth toe [S2PD
V]). All 39 individual items were scored with 1 or 0. A score
1 indicated abnormality on a test item (i.e., could not feel the
stimulus). The sum score per patient ranged from 0 to 39. In
addition to the 39 items on sensory loss, localized tibial nerve
compression over the tarsal tunnel was assessed using Tinel’s
sign.18 Both feet were examined.
Parametric Item Response Theory. We examined the psy-
chometric properties of the RDF-39 using parametric IRT
models. Supplementary Table SA provides deﬁnitions of the
terms used. A parametric IRT model compares the relative
ability of each individual test item to differentiate between
patient ability levels. Patients with a lower ability (more ill)
have a greater chance of obtaining an aberrant test result,
compared with patients with higher ability (less ill). This rela-
tionship is visualized by an item characteristic curve (ICC), in
which theta (θ) is a variable used to express a patient’s under-
lying ability (or trait) level, measured along the x-axis. The
probability of endorsing an item is given along the y-axis and
measured from 0 to 1. The location of the item (in log-odd
units, logits) on the latent trait (theta, in this study sensation
at the feet) represents the estimated difﬁculty of the item,
which is the mean of the threshold location. An example of
this relationship is that a patient with a history of diabetic foot
ulceration (more ill) is very unlikely to have a nonaberrant
S2PD test result at the hallux (less ill). Higher values on theta
represent greater levels of loss of foot sensation.
Fit Statistics. Fit statistics estimate how well the data match
model expectations. By using chi-square statistics, observed
data were compared with expected model values. Three para-
metric IRT models were considered: the 1-parameter logistic
(standard and extended Rasch) and 2-parameter logistic
(2PL) models. The standard Rasch model estimates a location
parameter for each item and assumes a common discrimina-
tion parameter (a) that is ﬁxed at 1. The extended Rasch
model, in contrast, estimates the common discrimination
parameter (i.e., not ﬁxed at 1). If the assumption of equal dis-
crimination does not hold, the 2PL-model can be used to esti-
mate both location and discrimination parameters for each
item. The ﬁtted models were compared with a likelihood ratio
test. Once a model appropriate for the data has been selected,
further tests of model and item ﬁt are executed.
Item Parameters. The most important parameters under
IRT are item location, discrimination and trait score. In this
study, binary RDF-39 items were considered, so item location
(b) (item difﬁculty) represents the location on the latent trait
(theta) where the probability of endorsing an item is 50%
(where the item functions best). Items with higher b values
represent more severe sensory loss. Item discrimination (a)
reﬂects the ability of an item to discriminate between patients
at different levels of the trait and is deﬁned as the slope of the
ICC at the item location. A steeper curve is indicative of better
discriminatory characteristics, with values closer to zero mean-
ing low discrimination power.
The items of the test battery were analyzed by calculating
the negative and positive responses per item. Cronbach’s
alpha assessed descriptively whether the items measured a
common construct (foot sensation, hence foot sensation
determines the item scores). To investigate which items fulﬁll
the Rasch assumption (i.e., which items have a discrimination
parameter equal to 1), we calculated the 95% conﬁdence
intervals for the discrimination parameters and checked for
which items the value 1 was included in the interval. The
probability of a positive response from the median patient was
calculated, i.e. the patient with theta value equal to zero.
ICCs and Item Information Curves. For all items, ICCs
were drawn that describe the relationship between a patient’s
underlying trait and how that patient responds to a dichoto-
mous item, together with corresponding item information
curves. An item information curve can be drawn for each item
to see in which range of theta values the speciﬁc item provides
information (y-axis) and to reveal how precision varies across
different levels of the underlying trait (x-axis). The amount of
test information per item is deﬁned as Ii (θ) at an ability level
of theta. In IRT, the concept of information reﬂects how
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precisely an item or scale can measure the underlying ability
(trait). Greater measurement precision is associated with
greater information and is inversely related to the standard
error of the estimate (theta). Thus, with more information a
smaller standard error of the estimated theta score is
obtained. Generally, more items provide more information.
To quantify the available information from all RDF-39 items,
we calculated the area under the total test information curve
in speciﬁc intervals of theta.
Theta Estimates. The trait score can be calculated after a
patient has responded to the items of the battery, to estimate
their position along the underlying trait (ability). Findings in
healthy volunteers without known neuropathy have been pub-
lished separately and are presented in this study for compara-
tive purposes.4
DIF. To investigate whether the items function differently
(so called item bias) in patients with respect to gender, type of
diabetes, age, duration of diabetes, complaints and signs of tib-
ial nerve compression at the tarsal tunnel, we tested for DIF
using the General Mantel-Haenszel method. This method
examines whether the odds of a symptomatic response within
each group on the measure is the same across subgroups, after
controlling for ability. Assessing DIF is important for valid
comparisons between subgroups of patients. Patients were
arbitrarily categorized, aiming for a logical and/or approxi-
mately equal distribution between the constructed groups.
Four age groups were identiﬁed by age (18–50 years, 51–60
years, 61–70 years, and >70 years); 4 by duration of diabetes
(0–10 years, 11–20 years, 21–30 years, > 30 years); and 3 by
the total score on the MNSI questionnaire as an indicator of
severity of experienced complaints of DSP (0 < 4: minor,
4 ≤ 7: intermediate, > 7 severe).
Statistics. Rasch and 2PL-model analyses were conducted
using the R packages “ltm” and “difR”.19,20 Missing data were
handled as part of the modeling process, but were rare (mean
per item: 2.0%, range: 0–5.8%), resulting in minimal bias.
Unidimensionality was assessed through principal components
analysis of the residuals. Other statistical analysis was carried
out using IBM’s SPSS Statistics 22.0 (IBM Corp., New York,
NY). Kolmogorov-Smirnov tests were used to assess normality.
Differences in continuous variables with skewed distributions
(theta) between 2 independent groups were assessed with
Mann-Whitney U tests. P-values < 0.05 (2-sided) were consid-
ered statistically signiﬁcant.
RESULTS
General Characteristics. A total of 416 RDF-study
participants with diabetes were included. Fifty-two
patients had a history of diabetic foot ulceration, for
which 13 underwent lower extremity amputations.
Further baseline characteristics are given in Table 1.
Fit Statistics. Excellent internal consistency of the
39 items was observed (Cronbach’s alpha > 0.938).
The likelihood ratio test between the estimated and
ﬁxed values of the common discrimination parame-
ter across items was (χ2 (df = 1) = 390.93; P < 0.001),
suggesting that the extended Rasch model, which
does not ﬁx the discrimination parameter to 1, pro-
vides a better ﬁt for the data. However, the
likelihood ratio test between the extended Rasch
model and the 2PL-model was (χ2 (df = 38) = 267.47;
P < 0.001), suggesting that the 2PL-model ﬁtted the
data better than the extended Rasch model. Hence,
for the remainder of this analysis we continued with
the 2PL-model.
Item Parameters (2PL-Model). Estimated difﬁculty
and discrimination parameters from the 2PL-model
are given per item in Table 2. In the ﬁrst column,
items are ordered according to the difﬁculty parame-
ter (from the item with the highest chance of a posi-
tive response to the item with the lowest probability
of a positive response, as indicated in the second col-
umn). Thus, item difﬁculty ranged from S2PD and
M2PD, ordered from those most likely representing
milder disease severity to items on severe sensory
loss. Speciﬁcally, items on S2PD, M2PD, vibration
sense, and S1PD were clustered, suggesting that for
all test sites the loss of S2PD and M2PD precedes the
loss of a protective sensation, as assessed with a 10-g
monoﬁlament. Of interest, complaints of numbness
are reported when S2PD, M2PD, vibration sense and
plantar S1PD items are already abnormal, suggesting
that the patient is unaware of the loss of these sen-
sory modalities.
The third column gives the probability of a posi-
tive response from the median diabetic patient.
Patients experiencing more sensory loss (i.e., having
a higher sum score) have a higher chance of scoring
positive on items with lower difﬁculty parameter
values (e.g., patients with a history of diabetic foot
Table 1. Demographic data
Gender (M/F) 241/175
Age (median (y), IQR) 64.0 (15.4)
Height (median (cm), IQR) 173.0 (15.8)
Weight (median (kg), IQR) 87.8 (26.5)
BMI (median (kg/m2), IQR) 29.4 (7.6)
Duration of diabetes (median (y), IQR) 16.0 (16)
Type of diabetes (n (%))
Type 1 93 (22.4%)
Type 2 323 (77.6%)
Drugs (n (%))
Lipid lowering drugs 267 (64.2%)
Oral blood glucose lowering drugs 229 (55.0%)
Insulin 351 (84.4%)
HbA1c (median (mmol/L), IQR) 60.0 (17.0)
MDRD (median ml/min/1.73 m, IQR) 77.9 (36.0)
Total cholesterol (median (mmol/L), IQR) 4.0 (1.3)
LDL-C (median (mmol/L), IQR) 1.8 (1.1)
HDL-C (median (mmol/L), IQR) 1.3 (0.5)
TG (median (median mmol/L), IQR) 1.6 (1.4)
Systolic blood pressure (median mmHg, IQR) 136.0 (23)
Diastolic blood pressure (median mmHg, IQR) 77.0 (13)
Diabetic sensory polyneuropathy (n (%)
MNSI score ≥ 4 148 (35.6%)
Retinopathy (n (%)) 59 (14.2%)
BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high density
lipoprotein; IQR, interquartile range; LDL, low density lipoprotein; MDRD,
Modiﬁcation of Diet in Renal Disease; M/F, male/female; TG, triglycerides.
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ulceration or amputation). The fourth column dis-
plays the discrimination parameter of each item that
quantiﬁes how well the corresponding item can dis-
criminate between patients, together with the 95%
conﬁdence interval of the discrimination parameter
(ﬁfth column). By checking which items were
included based on value 1, we investigated which
items fulﬁlled the Rasch assumption (equal discrimi-
nation across items). Ten items met this criterion
(Table 2).
Item Information Curves and Theta Estimates. The
total item information of all 39 items is given in a
plot (Fig. 1). The area under this curve was divided
into speciﬁc intervals on theta, to see from which
level item information is scarce. High logits indicate
more severe sensory loss. From -4 < theta < -3 the
available information was 0.5%, from -3 < theta < -2
3.1%, from -2 < theta < -1 15.9%, from -1 < theta < 0
26.5%, from 0 < theta < 1 21.9%, from 1 < theta < 2
19.4%, from 2 < theta < 3 7.5% and from 3 < theta <
4 3.5%. Most information is provided in the interval
of -2 < theta < 2. This may help to determine where
information from tests in areas of the trait is scarce.
The patient who scored nonaberrant on all items
(equal to zero) had a theta estimate of -2.17, whereas
the patient who scored all items aberrant had a theta
estimate of 3.21. Most patients fell in the ability
Table 2. Estimated difﬁculty and discrimination parameters from the 2PL-model.
Item
Difﬁculty
parameter value P (x=1 j z=0)
Discrimination
parameter value
95% conﬁdence
interval DIF due to
S2PD II left −1.076 .893 1.97 1.46 – 2.34 Neuropathy complaints
S2PD II right −1.040 .916 2.30 1.74 – 2.86 Type of diabetes
S2PD I left −0.984 .867 2.57 1.93 – 3.21
S2PD III left −0.929 .837 1.76 1.35 – 2.17
S2PD IV right −0.915 .881 2.18 1.68 – 2.69
S2PD V left −0.901 .897 2.40 1.85 – 2.96
S2PD V right −0.877 .943 3.21 2.42 – 4.00
S2PD I right −0.862 .900 2.55 1.97 – 3.13
S2PD IV left −0.844 .894 2.53 1.96 – 3.10
S2PD III right −0.839 .859 2.16 1.66 – 2.65
M2PD II left −0.657 .760 1.76 1.35 – 2.16 Gender, Tinel
M2PD III left −0.618 .757 1.84 1.42 – 2.26 Gender, type of diabetes, age
M2PD III right −0.580 .758 1.97 1.53 – 2.40 Gender
M2PD II right −0.416 .711 2.16 1.69 – 2.64
M2PD IV left −0.392 .665 1.75 1.36 – 2.15 Tinel
M2PD IV right −0.368 .683 2.09 1.62 – 2.56 Duration of diabetes
M2PD I left −0.279 .673 2.59 2.01 – 3.17 Gender, type of diabetes, age,
neuropathy complaints
M2PD I right −0.260 .648 2.34 1.81 – 2.87
Vibration sense IP
lefta
0.250 .429 1.14 0.86 – 1.42 Gender, age
Vibration sense IP
righta
0.250 .429 1.14 0.86 – 1.42 Gender, age
Vibration sense MM
righta
0.498 .384 0.95 0.70 – 1.20 Age
Vibration sense MM
lefta
0.601 .346 1.06 0.79 – 1.33 Age
S1PD I left 0.781 .094 2.90 2.17 – 3.64
S1PD I right 0.835 .117 2.43 1.83 – 3.02 Neuropathy complaints
S1PD V left 0.958 .079 2.57 1.93 – 3.21 Neuropathy complaints, Tinel
Numbnessa 0.960 .234 1.24 0.93 – 1.54 Type of diabetes, neuropathy
complaints, Tinel
S1PD V right 0.966 .070 2.67 1.99 – 3.36 Age, neuropathy complaints
S1PD II right 1.012 .145 1.75 1.33 – 2.18
S1PD II left 1.018 .144 1.75 1.33 – 2.17
S1PD III left 1.371 .012 3.23 2.33 – 4.13 Type of diabetes, neuropathy
complaints
S1PD III right 1.405 .022 2.71 1.98 – 3.43
S1PD IV left 1.532 .022 2.46 1.80 – 3.13
S1PD IV right 1.578 .026 2.29 1.68 – 2.90 Neuropathy complaints
Prior ulcer 1.696 .057 1.65 1.23 – 2.08 Neuropathy complaints
Cold stimulus lefta 1.812 .097 1.23 0.89 – 1.57 Gender
Cold stimulus righta 1.902 .091 1.21 0.88 – 1.54 Duration of diabetes
Romberg testa 2.157 .143 0.83 0.56 – 1.10 Gender, type of diabetes, age
Amputation lefta 3.159 .001 2.16 0.79 – 3.53
Amputation righta 3.322 .004 1.64 0.79 – 2.49
*Roman capitals are indicatives of test locations: I, hallux; II, medial heel; III, ﬁrst dorsal web; IV, lateral foot; V, ﬁfth toe. IP, interphalangeal joint; MM,
medial malleolus. For details on statistical information on DIF, see Supplementary Table SB.
aItems included based on discrimination parameter value 1.
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range of theta where much of items are situated,
indicating that the risk of ﬂoor and ceiling effects is
low (Fig. 2).
Figure 3 shows the theta distribution of diabetic
RDF-study participants compared with controls with-
out known neuropathy.
DIF. Minimal DIF was found in the items of the RDF-
39 (Table 2). Eight of 39 items showed DIF due to gen-
der. Six items showed DIF due to type of diabetes,
8 due to age, 2 due to a longer duration of diabetes,
9 due to increasing symptoms as indicated by the total
MNSI score and 4 due to signs of tibial nerve compres-
sion at the tarsal tunnel (Supplementary Table SB). By
investigating residual principal component loadings,
the RDF-39 was found to be unidimensional (propor-
tion of variance of ﬁrst principal component: 94.63%).
DISCUSSION
In this study, we investigated the measurement prop-
erties of the RDF-39 by ﬁtting parametric IRT
models to the data. Our analysis showed that it is
possible to grade sensory loss of the feet more pre-
cisely with a set of simple to use instruments on spe-
ciﬁc test locations. This grading presumably allows
for a more precise risk stratiﬁcation regarding, for
example, foot ulceration, amputation, and falls.
The effects of hyperglycemia and cardiovascular
risk factors produce morphological changes in the
structures of the peripheral and central nervous sys-
tem, resulting in dysfunction of the involved
tissues.21–23 Connective tissue and vascular structures
undergo changes as well, contributing to the com-
mon clinical entity of neuropathy.
Axonal loss occurs along the whole course of the
peripheral nerve but is most severe distally. Both mye-
linated and unmyelinated ﬁbers undergo changes.9,24,
Because the nerve ﬁbers innervating low-threshold
mechanoreceptors (LTMRs) are terminal parts of sen-
sory nerves, the skin of the foot is presumably the best
site to assess the functional status of both LTMRs and
its afferent ﬁbers, which degenerate more marked dis-
tally. Due to neuropathy, a combined loss of sensory
receptors and nerve ﬁbers may occur, that both con-
tribute to changed cutaneous threshold and innerva-
tion density.11 The results of the current study suggest
that as a result of this process the ability to discriminate
2 static points is lost ﬁrst, followed by the loss of mov-
ing 2-point discrimination, vibration sense, S1PD as
assessed with a 10-g monoﬁlament and cold sensation.
A strength of the RDF study is the broad range of
patients with varying degrees of sensory loss, includ-
ing patients with prior ulcerations and amputations.
The RDF-39 can be used to consecutively assess
patient sensory status and measure the incremental
sensory loss. Moreover, relative risks of adverse
events can also be estimated per consecutive item on
the scale, so that patients with absent vibration
thresholds have lower odds for ulceration than do
patients with prior ulcers or amputations.25 The dis-
tribution of patients at the upper and lower ends of
the trait makes ﬂoor and ceiling effects less likely, as
the total information curve suggests.
In many clinical situations, the assumptions of the
Rasch model do not hold due to its strict criteria,
while more complex models, like 2PL, ﬁt the data
better by estimation of item parameters. Our study
showed that 10 of 39 RDF items fulﬁll the require-
ments for good ﬁt of the Rasch-model and are
indicators of more severe sensory disability in the
feet, positioned on the right side of theta. In the
2PL-model we used, items investigating the loss of
S2PD, M2PD, and 10-g monoﬁlament testing were
included. These items provide information on areas
of the trait where Rasch model ﬁt items were not
present and, therefore, provide information on ear-
lier stages of sensory loss. Several checks, as part of
the 2PL-modeling process, found that no signiﬁcant
deviations between abilities and difﬁculties were pre-
sent, resulting in a model ﬁt of all 39 items.
Minimal DIF was found in the 39 items, which
allows us to make valid comparisons between
FIGURE 1. The total information curve of all items (n = 39) shows
the total test information along the trait (with Y = Ii (θ) * the
number of items in the test) and provides data on where test
information is scarce.
FIGURE 2. The distribution of patients along theta (in logits).
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subgroups. However, DIF indicates that comparisons
between subgroups should be made cautiously. Items
showing DIF due to age were most profound in
vibration sense items, which is explained by the prior
dichotomization of these items using normative
values for age.6 The type of diabetes resulted in dif-
ferences observed, among others, in abnormal Rom-
berg’s test and reported negative symptoms, mainly
attributable to the higher prevalence of type 2 diabe-
tes at an older age. Only 2 nonclinical signiﬁcant dif-
ferences were observed in items related to the
duration of diabetes (“M2PD IV right” and “Cold
stimulus right”). Patients with Tinel’s sign at the tar-
sal tunnel more frequently report signs of numbness
at the feet, a more frequent loss of protective sensa-
tion at the left ﬁfth toe and more abnormal scoring
of M2PD at the left heel and M2PD at the left lateral
foot. While it is ideal to only retain non–DIF-items, it
is possible to account and model for items with DIF
to preserve those items in a questionnaire or test bat-
tery. Further research on the predictive value of the
included items on conditions such as falls and ulcer-
ations will probably show that item reduction is possi-
ble, because items on S2PD and M2PD are clustered
and highly correlated.
Nerve entrapment is frequently observed in
patients with diabetes, in both the upper and lower
extremity, and might be partially responsible for sen-
sory disturbances, on top of the metabolic DSP.26–28
In our cohort, 44.5% of patients have a Tinel’s sign at
either the left or right tarsal tunnel. However, nerve
entrapment is difﬁcult to diagnose with nerve conduc-
tion studies in patients with symptoms of DSP.18,28,29
The fact that RDF-39 sensory tests in patients with
and without signs of nerve compression at the tarsal
tunnel do not exhibit abundant DIF suggests that the
loss of sensation due to DSP and concomitant com-
pression neuropathy is virtually the same. Sensitivity
to touch is an effective psychophysical measure of
peripheral nerve function and impairment. The
instruments used in the RDF-39 might be able to
detect earlier nerve dysfunction and complement
nerve conduction studies, which may be of impor-
tance in candidate selection for decompression of
entrapped tibial nerves at the tarsal tunnel.18,30,31 Pre-
sumably, patients without axonal loss have a better
chance of a beneﬁcial surgical outcome.18,28,32,33
However, further clinimetric properties of the RDF-
39, such as responsiveness after this type of surgery,
should be the subject of future studies.
An abundance of tests have been proposed in the
literature as early indicators of sensory loss.9,34,35
There is an increasing interest in the quantitative
assessment of small ﬁber damage as an early diagnos-
tic test and for monitoring progression of DSP.36
However, the exact temporal sequence of small and
large ﬁber damage is not fully understood. IRT can
help determine the place of tests in the progression
of the disease and categorize the consecutive loss
accordingly. In scale development, forms of IRT can
also be used to develop new unidimensional outcome
measures that are free from bias, because of the ideal
item response pattern.37,38 Furthermore, item banks
can be constructed so the measurement properties of
existing instruments, like nerve conduction studies,
can be investigated and compared.14,16,37
This study aids clinicians in the wider interdisci-
plinary ﬁeld of diabetic foot care in choosing an
appropriate instrument to assess loss of sensation in
the feet more precisely than by the use of a monoﬁl-
ament alone. By using these quick and simple instru-
ments, a more reliable estimation can be made of
FIGURE 3. Comparison between diabetic subjects and controls. Histograms of theta estimates in both groups show that median theta
scores (interquartile range) differed signiﬁcantly between individuals without known neuropathy (-0.924 [0.94]) and subjects with diabetes
(-0.088 [1.37]), P < 0.0005. Control subjects may experience some aberrancy in S2PD and M2PD items, but generally do have intact
vibration sensation and protective sensation, compared with diabetic subjects.
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the location of the patient in the natural history of
loss of sensation. Limitations are that we developed
the RDF-39 from a single-center population. There-
fore, external validity of our ﬁndings should be inves-
tigated in other settings, such as general practices,
academic hospitals and nursing homes. Further-
more, test–retest reliability should be investigated in
a group of diabetic subjects with varying degrees of
sensory loss, and responsiveness of the RDF-39
should be assessed during follow-up of the cohort.
This study establishes how current screening
instruments compare and where to apply them on
the feet, together with an outcome measure at the
interval level.16 Based on this information, a more
precise risk stratiﬁcation may be possible, with subse-
quent recommendations regarding interventions to
prevent complications such as foot ulcers and neuro-
genic arthropathy.39
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